[1] |
Takahashi S, Setoguchi Y, Nukiwa T, et al. interleukin-2 receptor in sear of patients with pulmonary TB. Chest, 1991, 99(2):310-314. doi: 10.1378/chest.99.2.310.
doi: 10.1378/chest.99.2.310
pmid: 1989787
|
[2] |
Rajalingam R, Mehra NK, Pande JN, et al. Correlation of serum interleukin-2 receptor alpha levels with clinical manifestations in pulmonary TB. Tuber Lung Dis, 1996, 77(4):374-379. doi: 10.1016/s0962-8479(96)90105-7.
doi: 10.1016/s0962-8479(96)90105-7
URL
|
[3] |
Harari A, Rozot V, Bellutti Enders F, et al. Dominant TNF-alpha+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med, 2011, 17(3):372-376. doi: 10.1038/nm.2299.
doi: 10.1038/nm.2299
URL
|
[4] |
Kumar NP, Moideen K, Banurekha VV, et al. Plasma Proinflammatory Cytokines Are Markers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis. Open Forum Infect Dis, 2019, 6(7):ofz257. doi: 10.1093/ofid/ofz257.
doi: 10.1093/ofid/ofz257
URL
|
[5] |
Bai R, Tao L, Li B, et al. Using cytometric bead arrays to detect cytokines in the serum of patients with different types of pulmonary tuberculosis. Int J Immunopathol Pharmacol, 2019, 33(12):2058738419845176. doi: 10.1177/20587384198 45176.
doi: 10.1177/20587384198 45176
|
[6] |
Zhong D, Dong L, Liang Q. Alteration of interferon-gamma and interleukin-12 released by bronchoalveolar lavage cells from pulmonary tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi, 2000, 23(9):552-555.
|
[7] |
Tsenova L, Bergtold A, Freedman VH, et al. Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system. Proc Natl Acad Sci U S A, 1999, 96(10):5657-5662. doi: 10.1073/pnas.96.10.5657.
doi: 10.1073/pnas.96.10.5657
pmid: 10318940
|
[8] |
Tobin DM, Vary JC Jr, Ray JP, et al. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell, 2010, 140(5):717-730. doi: 10.1016/j.cell.2010.02.013.
doi: 10.1016/j.cell.2010.02.013
pmid: 20211140
|
[9] |
Tsenova L, Sokol K, Freedman VH, et al. A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. J Infect Dis, 1998, 177(6):1563-1572. doi: 10.1086/515327.
doi: 10.1086/515327
pmid: 9607834
|
[10] |
Hong JY, Lee HJ, Kim SY, et al. Efficacy of IP-10 as a biomarker for monitoring tuberculosis treatment. J Infect, 2013, 68(3):252-258. doi: 10.1016/j.jinf.2013.09.033.
doi: 10.1016/j.jinf.2013.09.033
URL
|
[11] |
Adetifa IM, Ota MO, Jeffries DJ, et al. Interferon-γ ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection: a clinical trial. Am J Respir Crit Care Med, 2012, 187(4):439-445. doi: 10.1164/rccm.201208-1352OC.
doi: 10.1164/rccm.201208-1352OC
URL
|
[12] |
Azzurri A, Sow OY, Amedei A, et al. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect, 2005, 7(1):1-8. doi: 10.1016/j.micinf.2004.09.004.
doi: 10.1016/j.micinf.2004.09.004
URL
|
[13] |
Sharma S, Bose M. Role of cytokines in immune response to pulmonary tuberculosis. Asian Pac J Allergy Immunol, 2001, 19(3):213-219.
|
[14] |
Van Crevel R, Karyadi E, Preyers F, et al. Increased production of interleukin 4 by CD4+ and CD8+ T cells from patients with tuberculosis is related to the presence of pulmonary cavities. J Infect Dis, 2000, 181(3):1194-1197. doi: 10.1086/315325.
doi: 10.1086/315325
pmid: 10720554
|
[15] |
Lai CK, Ho S, Chan CH, et al. Cytokine gene expression profile of circulating CD4+ T cells in active pulmonary tuberculosis. Chest, 1997, 111(3):606-611. doi: 10.1378/chest.111.3.606.
doi: 10.1378/chest.111.3.606
pmid: 9118695
|
[16] |
Ameglio F, Casarini M, Capoluongo E, et al. Post-treatment changes of six cytokines in active pulmonary tuberculosis: differences between patients with stable or increased fibrosis. Int J Tuberc Lung Dis, 2005, 9(1):98-104.
pmid: 15675558
|
[17] |
Bai XJ, Li HM, Yang YR, et al. Cytokine and soluble adhesion molecule profiles and biomarkers for treatment monitoring in Re-treated smear-positive patients with pulmonary tuberculosis. Cytokine, 2018, 108(8):9-16. doi: 10.1016/j.cyto.2018.03.009.
doi: 10.1016/j.cyto.2018.03.009
URL
|
[18] |
Smith KA. Interleukin-2: inception, impact, and implications. Science, 1988, 240(4856): 1169-1176. doi: 10.1126/science.3131876.
doi: 10.1126/science.3131876
pmid: 3131876
|
[19] |
Pathan AA, Wilkinson KA, Klenerman P, et al. Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD 4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol, 2001, 167(9): 5217-5225. doi: 10.4049/jimmunol.167.9.5217.
doi: 10.4049/jimmunol.167.9.5217
pmid: 11673535
|
[20] |
Carrara S, Vincenti D, Petrosillo N, et al. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis, 2004, 38(5):754-756. doi: 10.1086/381754.
doi: 10.1086/381754
pmid: 14986262
|
[21] |
Katiyar SK, Sampath A, Bihari S, et al. Use of the Quanti-FERON-TB Gold In-Tube test to monitor treatment efficacy in active pulmonary tuberculosis. Int J Tuberc Lung Dis, 2008, 12(10): 1146-1152.
pmid: 18812044
|
[22] |
Pai M, Joshi R, Bandyopadhyay M, et al. Sensitivity of a whole-blood interferon-gamma assay among patients with pulmonary tuberculosis and variations in T-cell responses during anti-tuberculosis treatment. Infection, 2007, 35(2):98-103.
pmid: 17401714
|
[23] |
Dominguez J, De Souza-Galvao M, Ruiz-Manzano J, et al. T-cell responses to the Mycobacterium tuberculosis-specific antigens in active tuberculosis patients at the beginning, during, and after antituberculosis treatment. Diagn Microbiol Infect Dis, 2009, 63(1):43-51. doi: 10.1016/j.diagmicrobio.2008.09.010.
doi: 10.1016/j.diagmicrobio.2008.09.010
URL
|
[24] |
Kobashi Y, Mouri K, Yagi S, et al. Transitional changes in T-cell responses to Mycobacterium tuberculosis-specific antigens during treatment. J Infect, 2009, 58(3):197-204. doi: 10.1016/j.jinf.2008.08.009.
doi: 10.1016/j.jinf.2008.08.009
URL
|
[25] |
Sahiratmadja E, Alisjahbana B, De BT, et al. Dynamic changes in pro- and anti-inflammatory cytokine profiles and gamma interferon receptor signaling integrity correlate with tuberculosis disease activity and response to curative treatment. Infect Immun, 2007, 75 (2):820-829. doi: 10.1128/IAI.00602-06.
doi: 10.1128/IAI.00602-06
pmid: 17145950
|
[26] |
Oliveira de LR, Peresi E, Golim MA, et al. Analysis of toll-like receptors, iNOS and cytokine profiles in patients with pulmonary tuberculosis during anti-tuberculosis treatment. PLoS One, 2014, 9(2):e88572. doi: 10.1371/journal.pone.0088572.
doi: 10.1371/journal.pone.0088572
URL
|
[27] |
Deveci F, Akbulut HH, Turgut T, et al. Changes in serum cytokine levels in active tuberculosis with treatment. Med Inflamm, 2005(5): 256-262. doi: 10.1155/MI.2005.256.
doi: 10.1155/MI.2005.256
|